Biomarkers and Pe...
Follow
Find tag "egfr"
11.5K views | +6 today
Biomarkers and Personalized Medicine
Sharing relevant articles on advancements in personalized medicine
Curated by Brian Shields
Your new post is loading...
Your new post is loading...
Rescooped by Brian Shields from Lung Cancer Dispatch
Scoop.it!

Blood Protein Test Can Identify Lung Cancer Patients Likely to Benefit from Targeted Therapy

A recent phase III clinical trial confirmed that the VeriStrat test can predict which lung cancer patients are likely to fare better when treated with EGFR inhibitors like erlotinib (Tarceva). Patients with advanced non-small cell lung cancer (NSCLC) were tested using VeriStrat before beginning Tarceva treatment. Those who had a VeriStrat result of “Good” experienced longer times without cancer growth and longer overall survival on Tarceva compared to those with a “Bad” result. VeriStrat results may help doctors distinguish patients who should be given EGFR inhibitors from those for whom the benefits would not outweigh the side effects, and who would be better served by other treatments. VeriStrat does not test for mutations in the EGFR gene. Instead, the test assesses the pattern of several proteins in the blood to pinpoint patients likely to respond to EGFR inhibitors, including patients who may not have an EGFR mutation.


Via Cancer Commons
Brian Shields's insight:

Some interesting data out of ASCO using protien signatures in the blood to help develop personalized medicine for lung cancer patients.  Article excerpt follows:

The results from the Phase 3 trial announced today, shows it can make that difference, in a prospective study, which means that patients got the Biodesix test, were treated based on its recommendation, and followed over time to see if they ended up any better off. Passing that kind of rigorous study, should greatly expands the commercial potential for VeriStrat, Brunel said.

“VeriStrat has been commercially available for several years, but adoption has been limited…. This could lead to widespread adoption,” Brunel said.

According to the American Cancer Society, about 220,000 Americans per year are diagnosed with lung cancer, and about 85-90 percent have non-small cell lung cancer.

Biodesix will now build a national sales team and develop its marketing to try to capitalize on VeriStrat’s commercial potential, which could improve as the federal government is expected to reach a decision soon about whether it will be covered by Medicare.

more...
Cancer Commons's curator insight, June 6, 2013 5:38 AM

Xconomy | June 3, 2013

Scooped by Brian Shields
Scoop.it!

Dr. Kris on Dacomitinib in EGFR-Positive Lung Cancer

Dr. Kris on Dacomitinib in EGFR-Positive Lung Cancer | Biomarkers and Personalized Medicine | Scoop.it
Mark G. Kris, MD, from Memorial Sloan-Kettering Cancer Center, discusses the administration of dacomitinib for patient with EGFR-positive lung cancer.
Brian Shields's insight:

Very Positive data for patients in need of new treatments due to TKI resistance

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials

"Purpose: Anti-epidermal growth factor receptor (EGFR) agents [monoclonal antibodies (MoAbs), tyrosine kinase inhibitors (TKIs)] are targeted therapies used in advanced cancers. Arterial and venous thromboembolic events (ATEs and VTEs excluding catheter-related events) were not investigated with these agents, and the risk of these events is still unknown."

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

‘FRESH Science for Clinicians’: Combining EGFR and BRAF Inh... : Oncology Times

"Although the vast majority of melanoma patients with BRAF-mutant tumors respond to BRAF inhibitors, the same is not true for colon cancer patients with the mutation. One study reported that just 5% of colon cancer patients with BRAF-mutant tumors responded to the BRAF inhibitor vemurafenib. Now, data from a functional genomics screen may explain that paradox, researchers reported here at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference.

 

Remarkably, the data also suggest that combining an EGFR inhibitor with a BRAF inhibitor may dramatically improve responses in patients with BRAF-mutant colon cancer..."

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

BATTLE-2: Next-Generation of Biomarker-Driven Trials - OncLive

BATTLE-2: Next-Generation of Biomarker-Driven Trials - OncLive | Biomarkers and Personalized Medicine | Scoop.it
OncLive BATTLE-2: Next-Generation of Biomarker-Driven Trials OncLive While the number of known mutations and matching targeted agents is relatively limited at present, clinical trials are being designed to identify effective therapies for specific...
Brian Shields's insight:

The next-generation of clinical trials...Powerful quote in this article from Dr. Roy Herbst:


Are clinical trials like this going to be the wave of the future for developing new cancer therapies?

Herbst: Absolutely. I think it’s essential. If you don’t let the biology drive the treatment, everything is empiricism and it is going to have a very low chance of hitting the mark. So absolutely, as Dr Wistuba said, treat patients the best you can in real time, but also learn, discover, identify new markers.



This trial uses biomarkers to guide decisions, thereby providing patients with the best possible treatment arm, despite randomization.

more...
Nalina Nagarajan's curator insight, April 17, 2013 12:14 PM

A necessary development !!

Scooped by Brian Shields
Scoop.it!

Molecular Cancer, Volume 9, Number 1 - SpringerLink

Molecular Cancer, Volume 9, Number 1 - SpringerLink | Biomarkers and Personalized Medicine | Scoop.it

Wnt and EGFR signaling play key roles in embryonic development and cell proliferation. It is well documented that dysregulation of these two pathways often leads to tumorigenesis with poor prognosis. However, the possible crosstalk between the two pathways in cancer development is largely unknown. Although some reports show that EGFR might antagonize Wnt signaling during development in Drosophila, an increasing body of evidence indicates that Wnt and EGFR signaling crosstalk and transactivate one another in development and cancer. This review summarizes recent studies on the crosstalk between Wnt and EGFR signaling in cancers and points out several possible convergence points...

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Qiagen Receives Regulatory Approval in Japan for EGFR Companion Diagnostic to Guide Cancer Treatments

Qiagen Receives Regulatory Approval in Japan for EGFR Companion Diagnostic to Guide Cancer Treatments | Biomarkers and Personalized Medicine | Scoop.it
Qiagen today announced the regulatory approval of its therascreen EGFR Mutation Detection Kit RGQ in Japan.
more...
No comment yet.